| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Amgen Inc (NASDAQ: AMGN)
AMGN Technical Analysis
5
| As on 9th Jun 2023 AMGN SHARE Price closed @ 218.76 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 242.86 & Strong Sell for SHORT-TERM with Stoploss of 227.13 we also expect STOCK to react on Following IMPORTANT LEVELS. |
AMGNSHARE Price
| Open | 219.34 | Change | Price | % |
| High | 220.94 | 1 Day | -2.00 | -0.91 |
| Low | 217.77 | 1 Week | -1.89 | -0.86 |
| Close | 218.76 | 1 Month | -21.58 | -8.98 |
| Volume | 1707862 | 1 Year | -2.16 | -0.98 |
| 52 Week High 292.39 | 52 Week Low 214.27 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| AMGN Daily Charts |
AMGN Intraday Charts |
Whats New @ Bazaartrend |
AMGN Free Analysis |
|
|
AMGN Important Levels Intraday
| RESISTANCE | 224.87 |
| RESISTANCE | 222.91 |
| RESISTANCE | 221.70 |
| RESISTANCE | 220.49 |
| SUPPORT | 217.03 |
| SUPPORT | 215.82 |
| SUPPORT | 214.61 |
| SUPPORT | 212.65 |
AMGN Forecast April 2024
| 4th UP Forecast | 267.47 |
| 3rd UP Forecast | 251.85 |
| 2nd UP Forecast | 242.19 |
| 1st UP Forecast | 232.54 |
| 1st DOWN Forecast | 204.98 |
| 2nd DOWN Forecast | 195.33 |
| 3rd DOWN Forecast | 185.67 |
| 4th DOWN Forecast | 170.05 |
AMGN Weekly Forecast
| 4th UP Forecast | 233.25 |
| 3rd UP Forecast | 228.60 |
| 2nd UP Forecast | 225.73 |
| 1st UP Forecast | 222.86 |
| 1st DOWN Forecast | 214.66 |
| 2nd DOWN Forecast | 211.79 |
| 3rd DOWN Forecast | 208.92 |
| 4th DOWN Forecast | 204.27 |
AMGN Forecast2024
| 4th UP Forecast | 382.44 |
| 3rd UP Forecast | 329.95 |
| 2nd UP Forecast | 297.5 |
| 1st UP Forecast | 265.05 |
| 1st DOWN Forecast | 172.47 |
| 2nd DOWN Forecast | 140.02 |
| 3rd DOWN Forecast | 107.57 |
| 4th DOWN Forecast | 55.08 |
Amgen Inc ( NASDAQ USA Symbol : AMGN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
AMGN Business Profile
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service